Lataa...
Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma
There have been significant advances in the treatment of malignant melanoma with the U.S. Food and Drug Administration approval of two drugs in 2011, the first drugs approved in 13 years. The developments of immune checkpoint modulation via cytotoxic T-lymphocyte antigen-4 blockade, with ipilimumab,...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
AlphaMed Press
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4063399/ https://ncbi.nlm.nih.gov/pubmed/23709751 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0391 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|